Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines

The highly complementary profile of five best-in-class medicines consists of:-

  • Midkine antibodies with significant in vivo efficacy and toxicology studies;
  • Midkine oligonucleotide therapeutics with novel anti-cancer gene editing action;
  • Midkine mRNA therapeutics targeting solid tumours;
  • STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
  • MK cell therapy with direct and NK-mediated anti-cancer action.


3D protein enzyme clusters illustration lilac in colour on blue green background


Roquefort Therapeutic PLC Logo